PRESS RELEASE

SINOPHARM COVID-19 VACCINE IS NOW AVAILABLE IN MALAYSIA

KUALA LUMPUR, 15 October 2021 – Duopharma Biotech Berhad (“Duopharma Biotech” or

“the Company”) is further strengthening COVID-19 vaccination efforts in Malaysia with the
distribution of the Sinopharm COVID-19 vaccine. Earlier, Duopharma Biotech had entered into
an agreement to import the vaccine from Beijing, China, covering a collaboration for the
Malaysian market. Duopharma (M) Sdn. Bhd., a wholly owned subsidiary of Duopharma
Biotech has been authorised by Sinopharm as the product registration holder and to engage
in the sales and distribution of the vaccine.

In July 2021, the Ministry of Health’s Drug Control Authority (DCA) had approved the
conditional registration of the Sinopharm COVID-19 vaccine for use in Malaysia. The vaccine
is also included in the World Health Organization’s emergency use listing (EUL) and is
approved for emergency use in over 65 countries including in various European Union
countries, with more than 100 million doses supplied worldwide. In addition, Sinopharm is
among six brands of COVID-19 vaccines recognised by the Kingdom of Saudi Arabia, allowing
Muslims who have been administered with the vaccine to perform haj or umrah in Mecca. The
Sinopharm vaccine is currently indicated for use in individuals aged 18 to 59 years

“We are glad that Malaysia has managed to achieve a very high level of vaccination among
adults and is making good progress among adolescents. The challenge in overcoming the
COVID-19 pandemic requires collaboration and coordination at all levels. Duopharma Biotech
is committed to supporting the Government’s vaccination programme and augmenting the
National COVID-19 Immunisation Programme, by expanding vaccine distribution channels to
ensure full vaccine coverage in Malaysia,” said Leonard Ariff Abdul Shatar, Group Managing
Director of Duopharma Biotech.

Efficient administration process

The first shipments of the Sinopharm vaccine arrived in Malaysia in batches in September
2021, and is now widely available at clinics and private hospitals nationwide. With a shelf life
of 24 months, it is appropriate for longer term vaccination efforts. Additionally, the Sinopharm
vaccine is a convenient single-dose per vial of 0.5mL that helps to prevent wastage and easy
for planning vaccine administration. The vaccines cold chain storage is also straightforward
and easy, at a standard conventional storage temperature of 2°C to 8°C.
Administration of the vaccine is fully integrated into the national immunization system, where
the vaccines are tracked based on the Vaccine Management System provided by the Ministry
of Health, with real-time integration of both MyVAS and the MySejahtera app. Vaccinees
receiving their first and second doses will immediately have these recorded on their
MySejahtera accounts, and will also receive their digital certificate accordingly.

For vaccination of large groups, such as the workforce in manufacturing facilities, Duopharma
Biotech, via collaboration with healthcare organisers, provides private vaccination services as
well as mobile vaccine clinics, which is supported by a team of medical professionals,
paramedics, site managers and an operations and administration team.

Healthcare providers interested to procure the Sinopharm vaccine or corporations wishing to

arrange for vaccination may contact Duopharma Biotech’s Customer Service for enquiries via
email at cs@duopharmabiotech.com.

-End-
ABOUT DUOPHARMA BIOTECH BERHAD

Duopharma Biotech Berhad Group (“Duopharma Biotech” or “the Company”) began with the
establishment of Duopharma (M) Sendirian Berhad in 1978. Duopharma Biotech was
incorporated in the year 2000 and is today, one of Malaysia’s leading pharmaceutical
companies listed on the Main Market of Bursa Malaysia Berhad.

Duopharma Biotech has core competencies in the pharmaceutical industry inclusive of

Manufacturing, Research & Development and Commercialisation & Marketing of over 300
generic drugs - among others, Omesec and Prelica as well as its Consumer Healthcare (CHC)
products such as CHAMPS®, FLAVETTES®, PROVITON® and Uphamol, which are well
recognised and accepted by consumers in Malaysia, regionally and globally. The Company
has also diversified into the biosimilars space with technology and commercialisation
collaborations with credible and strong international partners.

The Company’s headquarters is located in Kuala Lumpur, Malaysia. Duopharma Biotech owns
and operates three manufacturing plants that are based in Klang, Bangi and Glenmarie,
Selangor. Duopharma Biotech also has subsidiary companies in the Philippines and
Singapore. A subsidiary of Duopharma Biotech Berhad has a representative office in Jakarta,
Indonesia.

Website: www.duopharmabiotech.com
For more information please contact: -

Rantau Golin
(Official Public Relations Agency of Duopharma Biotech Berhad)

Name : Adeline Phun / Ashley Elise

Telephone : 012-711 0075/012-388 6570
Email : duopharmabiotech@rantaupr.com.my

Corporate Communication Department of Duopharma Biotech Berhad

Name : Nor Soleha Ab Shukor / Delaila Abdullah

Telephone : +6019 289 1008 / +6012 296 9639
Email :soleha@duopharmabiotech.com/
delaila@duopharmabiotech.com